Robert Marcus
JPMorgan Chase & Co, Analysis Division
Good afternoon, everybody. I am Robbie Marcus, the MedTech analyst at JPMorgan. Actually pleased to current Benefit Medical. We now have new CEO, Martha Aronson. Martha goes to provide a presentation, after which we’ll do some Q&A after. Martha?
Martha Aronson
President, CEO & Director
Nice. Properly, thanks very a lot, Robbie, and thanks to JPMorgan for the chance at this time to talk to you all. Here is our forward-looking statements in addition to our non-GAAP monetary measures. So let me begin by simply saying that I am extraordinarily excited to be right here at this time as the brand new CEO of Benefit Medical. I am joined at this time additionally by Raul Parra, our CFO. Raul has been at Benefit for about 16 years and has served as our CFO for the final 7.5 years.
So for these of you I have not had the possibility to satisfy, once more, my title is Martha Aronson, and I used to be appointed CEO on October 3, 2025, succeeding our firm’s founder, Fred Lampropoulos. I’ve truly been within the business for a number of many years now, having labored at Medtronic and Hill-Rom previous to the Baxter acquisition in addition to the Ecolab Healthcare enterprise. As well as, I served on numerous Boards of Administrators within the final variety of years. And as I stated, I am simply so excited to be right here at Benefit Medical.
So I’ll take the time this afternoon to cowl a quick firm historical past, a bit of overview of our enterprise, our key merchandise, our go-to-market technique and what I believe is
